Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ryoko Suzuki, Jun Katada, Sreeram Ramagopalan & Laura McDonald. (2020) Potential of Machine Learning Methods to Identify Patients With Nonvalvular Atrial Fibrillation. Future Cardiology 16:1, pages 43-52.
Read now
Read now
Ameenathul M. Fawzy, Wang-Yang Yang & Gregory YH. Lip. (2019) Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety 18:3, pages 187-209.
Read now
Read now
Shun Kohsaka, Jun Katada, Kumiko Saito & Yasuo Terayama. (2018) Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Current Medical Research and Opinion 34:9, pages 1627-1634.
Read now
Read now
Articles from other publishers (37)
Xinsheng YanLitao ZhangDan ZhangXiaosu Wang. (2024) A real-world study of different doses of rivaroxaban in patients with nonvalvular atrial fibrillation. Medicine 103:17, pages e38053.
Crossref
Crossref
Naoko Unami & Yuya Ise. (2024) The Role of the Pharmacist in Clinical Settings (13): Estimation of Anticoagulant Activity of an Oral Anticoagulant Based on Patient Data from Nippon Medical School Hospital臨床現場における薬剤師の役割（13）. Nihon Ika Daigaku Igakkai Zasshi 20:1, pages 4-9.
Crossref
Crossref
J. J. Komen, N. B. Hunt, A. Pottegård, P. Hjemdahl, B. Wettermark, M. Olesen, M. Bennie, T. Mueller, R. Carragher, Ø. Karlstad, L. J. Kjerpeseth, O. H. Klungel & T. Forslund. (2023) Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. Pharmacoepidemiology and Drug Safety 32:11, pages 1223-1232.
Crossref
Crossref
Koji Miyamoto, Shunsuke Murata, Misa Takegami, Kenzaburo Nakajima, Tsukasa Kamakura, Mitsuru Wada, Kohei Ishibashi, Yuko Inoue, Satoshi Nagase, Takeshi Aiba, Kunihiro Nishimura & Kengo Kusano. (2023) Real-world comparison of in-hospital complications after catheter ablation for atrial fibrillation between non-antivitamin K anticoagulants and warfarin: A propensity-matched analysis using nation-wide database. IJC Heart & Vasculature 44, pages 101174.
Crossref
Crossref
Hongjin GaoYumei LiHong SunXiufang Huang, Hui Chen, Wei LinMin Chen. (2022) Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events. Journal of Cardiovascular Pharmacology 80:6, pages 869-876.
Crossref
Crossref
Jong Yop Pae, Eun Soo Kim, Sung Kook Kim, Min Kyu Jung, Jun Heo, Jang Hoon Lee & Min Ae Park. (2022) Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis. Intestinal Research 20:4, pages 482-494.
Crossref
Crossref
Hiroyuki Hashimoto, Shinobu Imai, Anna Kiyomi & Munetoshi Sugiura. (2022) Effectiveness and safety of extended treatment with direct oral anticoagulants for venous thromboembolism in Japan: A retrospective cohort study using claims data. Thrombosis Update 8, pages 100113.
Crossref
Crossref
Benjamin J. R. Buckley, Deirdre A. Lane, Peter Calvert, Juqian Zhang, David Gent, C. Daniel Mullins, Paul Dorian, Shun Kohsaka, Stefan H. Hohnloser & Gregory Y. H. Lip. (2022) Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:13, pages 3788.
Crossref
Crossref
Ze Li, Xiaozhen Wang, Dandan Li & Aiping Wen. (2022) Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis. Cardiology Research and Practice 2022, pages 1-10.
Crossref
Crossref
Yukihiro Koretsune, Haruhiko Hoshino, Yukako MatsuoTatsuki IbukiTakeshi Morimoto. (2022) Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation ― A Retrospective Chart Review Study ―. Circulation Journal 86:2, pages 213-221.
Crossref
Crossref
Zhimin Dong, Xiaoxia Hou, Xin Du, Liu He, Jianzeng Dong & Changsheng Ma. (2022) Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry. Clinical and Applied Thrombosis/Hemostasis 28, pages 107602962211233.
Crossref
Crossref
Mario Gaio, Carmen Ferrajolo, Alessia Zinzi, Consiglia Riccardi, Pasquale Di Filippo, Ludovica Carangelo, Gorizio Pieretti, Francesco Rossi, Giovanni Francesco Nicoletti & Annalisa Capuano. (2021) Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database – A Case Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Dong Lin, Yequn Chen, Jian Yong, Shiwan Wu, Yan Zhou, Weiping Li, Xuerui Tan & Ruisheng Liu. (2021) Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
A.L. Gagnon, B.A. Scansen, C. Olver, S. Shropshire, A. Hess & E.C. Orton. (2021) Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs. Journal of Veterinary Cardiology 36, pages 105-114.
Crossref
Crossref
Jun Qian, Yi-Dan Yan, Sheng-Yan Yang, Chi Zhang, Wen-Yan Li & Zhi-Chun Gu. (2021) Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies. Frontiers in Pharmacology 12.
Crossref
Crossref
Phatcharin Mitsuntisuk, Surakit Nathisuwan, Athirat Junpanichjaroen, Wanwarang Wongcharoen, Arintaya Phrommintikul, Phannita Wattanaruengchai, Wipharak Rattanavipanon, Suvatna Chulavatnatol, Nathorn Chaiyakunapruk, Khanchit Likittanasombat & Gregory Y. H. Lip. (2020) Real‐World Comparative Effectiveness and Safety of Non‐Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. Clinical Pharmacology & Therapeutics 109:5, pages 1282-1292.
Crossref
Crossref
Wei-Jia Li, Paraschos Archontakis-Barakakis, Leonidas Palaiodimos, Dimitrios Kalaitzoglou, Lazaros Tzelves, Apostolos Manolopoulos, Yu-Chiang Wang, Stefanos Giannopoulos, Robert Faillace & Damianos G Kokkinidis. (2021) Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. World Journal of Cardiology 13:4, pages 82-94.
Crossref
Crossref
Naoko Unami, Yuya Ise & Hidenori Suzuki. (2020) Anticoagulant activity of apixaban can be estimated by multiple regression analysis. Journal of Arrhythmia 36:6, pages 1032-1038.
Crossref
Crossref
Xiaoping Wang, Lili Fang, Bin Liu, Yongliang Zheng & Junquan Zeng. (2019) Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis. Heart Failure Reviews 25:6, pages 973-983.
Crossref
Crossref
Zhengbiao Xue, Yue Zhou, Chaoyu Wu, Jie Lin, Xin Liu & Wengen Zhu. (2019) Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. Heart Failure Reviews 25:6, pages 957-964.
Crossref
Crossref
Wanwarang Wongcharoen, Phongsathon Pacharasupa, Lalita Norasetthada, Siriluck Gunaparn & Arintaya Phrommintikul. (2020) Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation. Circulation Journal 84:7, pages 1075-1082.
Crossref
Crossref
Masahiro Yasaka, Shinichiro Uchiyama, Hirotsugu Atarashi, Ken Okumura, Yukihiro Koretsune, Takeshi Yamashita, Atsushi Taniguchi, Taku Fukaya & Hiroshi Inoue. (2020) Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program. Journal of Stroke and Cerebrovascular Diseases 29:5, pages 104717.
Crossref
Crossref
Shun Kohsaka, Jun Katada, Kumiko Saito, Aaron Jenkins, Benjamin Li, Jack Mardekian & Yasuo Terayama. (2020) Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart 7:1, pages e001232.
Crossref
Crossref
Jianchao Zhang, Junnan Tang, Xiaolin Cui, Bo Wang, Mengsen Bu, Yan Bai, Kai Wang, Jiacheng Guo, Deliang Shen & Jinying Zhang. (2019) Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis. BMC Cardiovascular Disorders 19:1.
Crossref
Crossref
Yi-Hsin Chan, Hsin-Fu Lee, Tze-Fan Chao, Chia-Tung Wu, Shang-Hung Chang, Yung-Hsin Yeh, Lai-Chu See, Chi-Tai Kuo, Pao-Hsien Chu, Chun-Li Wang & Gregory Y. H. Lip. (2019) Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. Cardiovascular Drugs and Therapy 33:6, pages 701-710.
Crossref
Crossref
Jessika Lobraico-Fernandez, Salma Baksh & Eric Nemec. (2019) Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies. Drugs in R&D 19:3, pages 235-245.
Crossref
Crossref
Jacques Bouget, Frédéric Balusson, Lucie‐Marie Scailteux, Maxime Maignan, Pierre‐Marie Roy, Erwan L'her, Laure Pavageau & Emmanuel Nowak. (2019)
Major bleeding with antithrombotic agents: a 2012–2015 study using the French nationwide Health Insurance database linked to emergency department records within five areas – rationale and design of
SACHA
study
. Fundamental & Clinical Pharmacology 33:4, pages 443-462.
Crossref
Crossref
Hiroshi Inoue, Shinichiro Uchiyama, Hirotsugu Atarashi, Ken Okumura, Yukihiro Koretsune, Masahiro Yasaka, Takeshi Yamashita, Atsushi Taniguchi & Taku Fukaya. (2019) WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance. Journal of Cardiology 74:2, pages 156-163.
Crossref
Crossref
Hiroshi Inoue, Shinichiro Uchiyama, Hirotsugu Atarashi, Ken Okumura, Yukihiro Koretsune, Masahiro Yasaka, Takeshi Yamashita, Atsushi Taniguchi & Taku Fukaya. (2019) Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. Journal of Cardiology 73:6, pages 507-514.
Crossref
Crossref
Hiroshi Inoue, Michiaki Umeyama, Takako Yamada, Hiroyuki Hashimoto, Akira Komoto & Masahiro Yasaka. (2019)
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the
STANDARD
study
. Journal of Arrhythmia 35:3, pages 506-514.
Crossref
Crossref
Zhe Sun, Yuqi Liu, Ye Zhang, Xinhong Guo & Yong Xu. (2019) Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis. International Journal of Clinical Practice 73:4, pages e13308.
Crossref
Crossref
Daniela Fialová, Blanca Laffon, Valentina Marinković, Ljiljana Tasić, Peter Doro, Gyӧngyver Sόos, Jorge Mota, Soner Dogan, Jovana Brkić, João Paulo Teixeira, Vanessa Valdiglesias & Solange Costa. (2019) Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies). European Journal of Clinical Pharmacology 75:4, pages 451-466.
Crossref
Crossref
Yukihiro Koretsune, Takeshi Yamashita, Masahiro Yasaka, Yasuhisa Ono, Takeshi Hirakawa, Kosuke Ishida, Daisuke Kuroki, Toshiyuki Sumida & Hisashi Urushihara. (2019) Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis. Journal of Cardiology 73:3, pages 204-209.
Crossref
Crossref
Tomohiko Ono, Nobuhiro Ikemura, Takehiro Kimura, Ikuko Ueda, Hiroaki Tanaka, Hanako Tokuda, Noriyuki Yajima, Keisuke Matsumura, Masahiro Suzuki, Keiichi Fukuda, Shun Kohsaka & Seiji Takatsuki. (2019) Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry. Journal of Cardiology 73:1, pages 14-21.
Crossref
Crossref
Yi-Cheng Lin, Shu-Chen Chien, Yi-Chen Hsieh, Chun-Ming Shih, Feng-Yen Lin, Nai-Wen Tsao, Chih-Wei Chen, Yung-Ta Kao, Kuang-Hsing Chiang, Wan-Ting Chen, Li-Nien Chien & Chun-Yao Huang. (2018) Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation. Journal of the American College of Cardiology 72:5, pages 477-485.
Crossref
Crossref
Toru OGURA. (2018) The role of statistics analysis in clinical and database research on venous thromboembolism静脈血栓塞栓症の臨床研究とデータベース研究における統計学の役割. Japanese Journal of Thrombosis and Hemostasis 29:4, pages 374-378.
Crossref
Crossref
Zhimin Dong, Xiaoxia Hou, Xin Du, Liu He, Jianzeng Dong & Changsheng Ma. (2022) Effectiveness and Safety of Rivaroxaban and Dabigatran in Non-Valvular Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry. SSRN Electronic Journal.
Crossref
Crossref